中国综合临床
中國綜閤臨床
중국종합림상
Clinical Medicine of China
2015年
11期
992-995
,共4页
拉呋替丁%消化性溃疡%兰索拉唑%胃镜检查
拉呋替丁%消化性潰瘍%蘭索拉唑%胃鏡檢查
랍부체정%소화성궤양%란색랍서%위경검사
Lafutidine%Peptic ulcer%Lansoprazole%Gastroscope examination
目的 观察拉呋替丁治疗消化性溃疡的临床效果.方法 将84例消化性溃疡患者随机分为治疗组42例和对照组42例.治疗组给予拉呋替丁胶囊10 mg,每天2次口服;对照组给予兰索拉唑片30 mg,每天1次口服.两组均连续服用4周.观察治疗后溃疡愈合情况及临床症状的缓解情况.结果 用药第1、3、7天治疗组症状缓解率与对照组差异均无统计学意义[23.81％(10/42)与38.09％(16/42)、76.19％ (32/42)与71.42％ (30/42)、85.71％ (36/42)与90.47％ (38/42),P值分别为0.157、0.620、0.736].治疗4周后胃镜检查结果显示,治疗组的完全愈合率、基本愈合率、临床总有效率与对照组比较差异均无统计学意义[57.14％ (24/42)与61.90％(26/42)、28.57％(12/42)与30.95％ (13/42)、95.23％(40/42)与97.61％(41/42),P值分别为0.657、0.811、1.000].治疗过程中两组均未发生严重不良反应.结论 拉呋替丁用于治疗消化性溃疡可有效促进溃疡愈合,改善患者临床症状,效果与兰索拉唑相近.
目的 觀察拉呋替丁治療消化性潰瘍的臨床效果.方法 將84例消化性潰瘍患者隨機分為治療組42例和對照組42例.治療組給予拉呋替丁膠囊10 mg,每天2次口服;對照組給予蘭索拉唑片30 mg,每天1次口服.兩組均連續服用4週.觀察治療後潰瘍愈閤情況及臨床癥狀的緩解情況.結果 用藥第1、3、7天治療組癥狀緩解率與對照組差異均無統計學意義[23.81％(10/42)與38.09％(16/42)、76.19％ (32/42)與71.42％ (30/42)、85.71％ (36/42)與90.47％ (38/42),P值分彆為0.157、0.620、0.736].治療4週後胃鏡檢查結果顯示,治療組的完全愈閤率、基本愈閤率、臨床總有效率與對照組比較差異均無統計學意義[57.14％ (24/42)與61.90％(26/42)、28.57％(12/42)與30.95％ (13/42)、95.23％(40/42)與97.61％(41/42),P值分彆為0.657、0.811、1.000].治療過程中兩組均未髮生嚴重不良反應.結論 拉呋替丁用于治療消化性潰瘍可有效促進潰瘍愈閤,改善患者臨床癥狀,效果與蘭索拉唑相近.
목적 관찰랍부체정치료소화성궤양적림상효과.방법 장84례소화성궤양환자수궤분위치료조42례화대조조42례.치료조급여랍부체정효낭10 mg,매천2차구복;대조조급여란색랍서편30 mg,매천1차구복.량조균련속복용4주.관찰치료후궤양유합정황급림상증상적완해정황.결과 용약제1、3、7천치료조증상완해솔여대조조차이균무통계학의의[23.81％(10/42)여38.09％(16/42)、76.19％ (32/42)여71.42％ (30/42)、85.71％ (36/42)여90.47％ (38/42),P치분별위0.157、0.620、0.736].치료4주후위경검사결과현시,치료조적완전유합솔、기본유합솔、림상총유효솔여대조조비교차이균무통계학의의[57.14％ (24/42)여61.90％(26/42)、28.57％(12/42)여30.95％ (13/42)、95.23％(40/42)여97.61％(41/42),P치분별위0.657、0.811、1.000].치료과정중량조균미발생엄중불량반응.결론 랍부체정용우치료소화성궤양가유효촉진궤양유합,개선환자림상증상,효과여란색랍서상근.
Objective To observe the clinical efficacy and safety of application of lafutidine treated in curing peptic ulcer.Methods Eighty-four patients with peptic ulcer were randomly assigned to receive either lafutidine(10 mg) twice daily in 42 patients of cured group or lansoprazole (30 mg) once daily for 4 weeks in 42 patients of control group.Ulcer healing rate and clinical performance were examined after treatment.Results The first,third and seventh day of peptic ulcer healing rate were 38.09％ (16/42), 71.42％ (30/42) and 90.47％ (38/42) in the lansoprazole group and 23.81％ (10/42), 76.19％ (32/42) and 85.71％ (36/42) in the lafutidine group.There were no siginificant difference between two groups (P =0.157,0.620, 0.736).Gastroscope examination showed the complete healing rate, average healing rate and general clinical effectiveness were 61.90％(26/42) ,30.95％(13/42) and 97.61％(41/42) in the lansoprazole group,while the number for lafutidine group were 57.14％ (24/42), 28.57％ (12/42) and 95.23％ (40/42).There were no siginificant difference between two groups (P =0.657, 0.811, 1.000).No severe side-effect was occurred in both groups.Conclusion Use Lafutidine to cure peptic ulcer can promote healing effectively, improve patients' clinical symptoms which is similar to lansoprazole.
